Houston, TXNCT06590961Now EnrollingIRB Ready

Relapsed/Refractory B-cell Malignancies Clinical Trial in Houston, TX

Access cutting-edge relapsed/refractory b-cell malignancies treatment through this clinical trial at a research site in Houston. Study-provided care at no cost to qualified participants.

Sponsored by Ubix Therapeutics, Inc.

Quick Self-Assessment

See if you qualify for this Houston location

Preparing your pre-screening questions…

Expert Care in Houston

Access relapsed/refractory b-cell malignancies specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related relapsed/refractory b-cell malignancies treatment provided free

Apply for This Houston Location

Check if you qualify for this relapsed/refractory b-cell malignancies clinical trial in Houston, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Houston

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Houston site if eligible
  4. 4Begin participation

About This Relapsed/Refractory B-cell Malignancies Study in Houston

This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of UBX-303061 in patients with relapsed/refractory B-cell malignancies.

Sponsor: Ubix Therapeutics, Inc.

Who Can Participate

Inclusion Criteria

Capable of giving signed informed consent
Age ≥18 years
ECOG performance status ≤2.
Phase Ia (dose-escalation part only): Subjects with relapsed and/or refractory B-cell malignancies (CLL/SLL, DLBCL, FL, MCL, WM or MZL) who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion.
Phase Ib (dose-expansion only): Subjects with relapsed and/or refractory B-cell malignancies who have received at least 2 prior therapies and for subjects with no available treatment options as per the Investigator's discretion, and fit into one of the following groups: CLL/SLL or DLBCL or MCL or FL, WM, MZL
All subjects must have evaluable or measurable disease based on the appropriate tumor type criteria
Adequate organ and bone marrow function Key

Exclusion Criteria

For subjects with lymphoma:
Systemic antineoplastic therapy or any experimental therapy within 3 weeks or 5 half-lives, whichever is shorter, before the first dose of study treatment.
Therapy with tyrosine kinase inhibitor within 5 half-lives before the first dose of study treatment.
Unconjugated monoclonal antibody therapies \<6 weeks before the first dose of study treatment.
Subjects that have undergone autologous stem cell rescue within 100 days prior to the first dose of study treatment.
Subjects that have undergone allogeneic stem cell transplant within 6 months prior to the first dose of study treatment.
Subjects with active graft-versus-host disease (GVHD) or on anti-GVHD treatment or prophylaxis.
History of chimeric antigen receptor T cell (CAR-T) therapy within 100 days prior to start of study drug.
Any immunotherapy within 4 weeks of first dose of study drug.
The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drug is \<5 times the t1/2 of the previously administered agent(s).
Previously exposed to BTK degradation therapy
Malignant disease, other than that being treated in this study.
Radiotherapy within 2 weeks of the first dose of study treatment
Known hypersensitivity to BTK degraders or any of the ingredients.
Impaired cardiac function or clinically significant cardiac disease
Subjects with history of severe bleeding disorders and known/suspected other autoimmune disease
Major surgery within 4 weeks of the first dose of study treatment

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Houston?

Yes, this clinical trial (NCT06590961) has an active research site in Houston, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Relapsed/Refractory B-cell Malignancies Treatment Options in Houston, TX

If you're searching for relapsed/refractory b-cell malignancies treatment options in Houston, TX, this clinical trial (NCT06590961) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Houston research site is actively enrolling participants for this clinical trial. You'll receive care from experienced relapsed/refractory b-cell malignancies specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all relapsed/refractory b-cell malignancies clinical trials near you to find additional studies recruiting in your area.

More Rheumatoid Arthritis Trials in Houston, TX

See all rheumatoid arthritis clinical trials recruiting in Houston — not just this study.

Browse Rheumatoid Arthritis Trials in Houston →

Browse More Trials by Condition

Rheumatoid Arthritis TrialsAntiphospholipid Syndrome TrialsErectile Dysfunction TrialsAll Conditions →

Ready to Join in Houston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Houston, TX